Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
94 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Hearing Disorders - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Hearing Disorders - Pipeline Review, H2 2014', provides an overview of the Hearing Disorders's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hearing Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hearing Disorders and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hearing Disorders - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hearing Disorders and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hearing Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hearing Disorders pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hearing Disorders - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hearing Disorders pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Hearing Disorders Overview 9 Therapeutics Development 10 Pipeline Products for Hearing Disorders - Overview 10 Pipeline Products for Hearing Disorders - Comparative Analysis 11 Hearing Disorders - Therapeutics under Development by Companies 12 Hearing Disorders - Therapeutics under Investigation by Universities/Institutes 14 Hearing Disorders - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Hearing Disorders - Products under Development by Companies 18 Hearing Disorders - Products under Investigation by Universities/Institutes 19 Hearing Disorders - Companies Involved in Therapeutics Development 20 Affichem 20 AudioCure Pharma GmbH 21 Edison Pharmaceuticals, Inc. 22 Fate Therapeutics, Inc. 23 Living Cell Technologies Limited 24 Novartis AG 25 Otologic Pharmaceutics, Inc. 26 Pharmicell Co., Ltd. 27 Quark Pharmaceuticals, Inc. 28 Sound Pharmaceuticals, Inc. 29 uniQure NV 30 Hearing Disorders - Therapeutics Assessment 31 Assessment by Monotherapy Products 31 Assessment by Combination Products 32 Assessment by Target 33 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 (acetylcysteine + disufenton sodium) - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 AC-002 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 AC-102 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 AC-103 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 AC-104 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 AF-243 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 AMT-090 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 AUT-00063 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Cellgram for Severe Hard of Hearing - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 CGF-166 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Drugs to Inhibit Rho Kinase for Hearing Loss - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Neuroprotectin D1 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 NTCELL - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 OT-0001 Analogs - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 P-13 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 siRNA for CNS Disorders - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Small Molecules to Inhibit Gamma Secretase for Hearing Loss - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 sodium thiosulfate - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 SPI-1005 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 SPI-3005 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 SPI-5557 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Stem Cell Therapy for Hearing Disorders - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 transplatin - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 vatiquinone - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Hearing Disorders - Recent Pipeline Updates 72 Hearing Disorders - Dormant Projects 81 Hearing Disorders - Discontinued Products 82 Hearing Disorders - Product Development Milestones 83 Featured News & Press Releases 83 Jun 02, 2014: Adherex Announces Results From Two Sodium Thiosulfate Phase 3 Studies Presented at the 50th American Society of Clinical Oncology Meeting 83 Apr 22, 2014: Adherex Announces Two Sodium Thiosulfate Presentations for Prevention of Ototoxicity in Children at ASCO Meeting 85 Nov 05, 2013: Sound Pharmaceuticals successfully completes its first Phase 2 clinical trial with SPI-1005 involving iPod or noise induced hearing loss 86 Oct 07, 2011: Adherex Reports Meeting With FDA'S Pediatric Subcommittee Of Oncologic Drugs Advisory Committee On Development Of Sodium Thiosulfate Injection 87 Jun 28, 2010: Fate Therapeutics Receives Red Herring's North America 100 Award For Advancing Stem Cell Technology And New Medicines 87 Feb 04, 2010: Fate Therapeutics Receives Allowance Of First U.S. Patent For Induced Pluripotent Stem Cell Technology 88 Dec 01, 2009: Fate Therapeutics' IPSC Technology Awarded Top Industry Honors For Small Molecule And Protein Reprogramming Breakthroughs 89 Nov 16, 2009: Fate Therapeutics Closes $30 Million Series B Financing 90 Aug 19, 2009: Sound Pharmaceuticals Receives An Office of Naval Research Award for Its Hearing Loss Research and Development 91 Jul 23, 2008: Sound Pharmaceuticals Files Second IND with the FDA For The Prevention Of Chemotherapy Induced Hearing Loss In Advanced Stage Cancer 91 Appendix 93 Methodology 93 Coverage 93 Secondary Research 93 Primary Research 93 Expert Panel Validation 93 Contact Us 94 Disclaimer 94
List of Tables Number of Products under Development for Hearing Disorders, H2 2014 10 Number of Products under Development for Hearing Disorders - Comparative Analysis, H2 2014 11 Number of Products under Development by Companies, H2 2014 13 Number of Products under Investigation by Universities/Institutes, H2 2014 14 Comparative Analysis by Late Stage Development, H2 2014 15 Comparative Analysis by Clinical Stage Development, H2 2014 16 Comparative Analysis by Early Stage Development, H2 2014 17 Products under Development by Companies, H2 2014 18 Products under Investigation by Universities/Institutes, H2 2014 19 Hearing Disorders - Pipeline by Affichem, H2 2014 20 Hearing Disorders - Pipeline by AudioCure Pharma GmbH, H2 2014 21 Hearing Disorders - Pipeline by Edison Pharmaceuticals, Inc., H2 2014 22 Hearing Disorders - Pipeline by Fate Therapeutics, Inc., H2 2014 23 Hearing Disorders - Pipeline by Living Cell Technologies Limited, H2 2014 24 Hearing Disorders - Pipeline by Novartis AG, H2 2014 25 Hearing Disorders - Pipeline by Otologic Pharmaceutics, Inc., H2 2014 26 Hearing Disorders - Pipeline by Pharmicell Co., Ltd., H2 2014 27 Hearing Disorders - Pipeline by Quark Pharmaceuticals, Inc., H2 2014 28 Hearing Disorders - Pipeline by Sound Pharmaceuticals, Inc., H2 2014 29 Hearing Disorders - Pipeline by uniQure NV, H2 2014 30 Assessment by Monotherapy Products, H2 2014 31 Assessment by Combination Products, H2 2014 32 Number of Products by Stage and Target, H2 2014 34 Number of Products by Stage and Mechanism of Action, H2 2014 36 Number of Products by Stage and Route of Administration, H2 2014 38 Number of Products by Stage and Molecule Type, H2 2014 40 Hearing Disorders Therapeutics - Recent Pipeline Updates, H2 2014 72 Hearing Disorders - Dormant Projects, H2 2014 81 Hearing Disorders - Discontinued Products, H2 2014 82
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.